Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
Public ClinicalTrials.gov record NCT02159859. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.
Study identification
- NCT ID
- NCT02159859
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 88 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Mar 31, 2016
- Completion
- Mar 31, 2016
- Last update posted
- Oct 16, 2018
2014 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oakwood Hospital - Dearborn | Dearborn | Michigan | 48124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated End Stage Renal Disease trials
Other public records listing End Stage Renal Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT04163614: Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients Recruiting
- NCT06516653: Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula Recruiting
- NCT07696962: Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease Not yet recruiting
- NCT04392206: AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses Recruiting
- NCT03674307: Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates Active, not recruiting
- NCT06422871: PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02159859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2018 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02159859 live on ClinicalTrials.gov.